Navigation Links
Debiopharm in Medical News

Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories

PARIS and LAUSANNE, Switzerland, Oct. 31 /PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN) and Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions today announced the extension of their agreement, whereby Ips...

Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA

...e TRELSTAR(R) NDA was prepared in cooperation with debiopharm Group, a Swiss-based global biopharmaceutical grou...bout TRELSTAR (R) TRELSTAR(R), developed by debiopharm Group and marketed by Watson, administers a synthe...e at http://www.watson.com . About debiopharm Group ...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

... of Celgosivir II-59 Pharmasset Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 debiopharm Releases Phase Ib Results of Debio 025 II-59 Nabi Biopharmaceuticals Starts Proof-Of-Concept Trial for Civacir II-60 Peregrine Announces Posit...

Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer

...e for men and their physicians and will be a significant addition to our expanding urology portfolio." About TRELSTAR(R) TRELSTAR(R), developed by debiopharm Group, a Swiss biopharmaceutical development specialist, and marketed by Watson Pharma, Inc., is a synthetic hormone known as a luteinizing hormone re...

Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

... LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- debiopharm Group (Debiopharm), a global independent biopharma...d Rolland-Yves Mauvernay, president and founder of debiopharm Group. "This demonstrates our ability to work effe...y marketed by Watson Pharmaceuticals, Inc. About debiopharm Group ...

Investigational drug tested for preventing muscle fiber death in muscular dystrophy

...ilin D and blocks cell death in a number of situations, the drug does not suppress the immune system or block calcineurin. The drug is manufactured by debiopharm S.A. of Lausanne, Switzerland, which provided Debio-025 for use in the study. The researchers also found their study may have implications beyond ...

Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology

...rier, currently in late preclinical development by debiopharm for use in oncology. Phase I clinical studies are ... the terms of the agreement: - NanoCarrier grants debiopharm an exclusive license, with the right to sublicense...in Polymeric Micelle worldwide excluding Japan. - debiopharm will provide NanoCarrier exclusively with the star...

Ranbaxy to Market Debiopharm's New Drug in India

...t with Swiss biopharmaceutical development company debiopharm Group to// market its new gastro-enterology drug. ...is presently undergoing Phase III clinical trials. debiopharm expects to file Sanvar for approval in the US in f...uarter of 2007. "We are glad to partner with debiopharm in the gastro-enterology area and shall work towar...
Debiopharm in Medical Technology

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissme...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissme...

Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND

LAUSANNE, Switzerland, October 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today that the first healthy elderly subjects have been randomised in a clinical bi...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

...diabetes. Under the terms of the agreement, debiopharm shall pay Mercury for continued research and devel...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group." "This alliance with debiopharm represents important validation of Mercury's techn...

Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

... LAUSANNE, Switzerland, June 23 /PRNewswire/ -- debiopharm Group (Debiopharm), a Swiss-based global biopharma...). There are also fewer side effects. About debiopharm Group debiopharm Group is a Swiss-based global biopharmaceutical gr...

Clinical Update - Debio 025 in Hepatitis C

... LAUSANNE, Switzerland, April 28 /PRNewswire/ -- debiopharm Group (Debiopharm), a global biopharmaceutical dev...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group. "We are making it our mission to find a cur... About the phase IIa triple therapy study debiopharm investigated different dosing regimens of Debio 02...

Clinical Update - Debio 025 in Hepatitis C

... LAUSANNE, Switzerland, January 26 /PRNewswire/ -- debiopharm Group (Debiopharm), a global biopharmaceutical dev...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group. "With over 170 million people infect...we hope to address," added Kamel Besseghir, CEO of debiopharm S.A. About Debio 025 Debio 025 is a ...

Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding

... debiopharm Submits Response to the FDA LAUSANNE, Switzerland, November 4 /PRNewswire/ -- debiopharm Group (Debiopharm), a global biopharmaceutical dev...d Rolland-Yves Mauvernay, president and founder of debiopharm Group. "Last summer, we completed a confirmatory...

Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients

...AUSANNE, Switzerland, September 25 /PRNewswire/ -- debiopharm Group (Debiopharm), a global biopharmaceutical dev...enience and comfort," said Kamel Besseghir, CEO of debiopharm S.A. "Furthermore, upon approval, our newly built ... licensee sales are in excess of US $400M. About debiopharm Group ...

Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment

...LAUSANNE, Switzerland, September 2 /PRNewswire/ -- debiopharm Group (Debiopharm), a global independent biopharma... standard therapies," said Kamel Besseghir, CEO of debiopharm S.A. About debiopharm Group ...
Debiopharm in Biological Technology

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a drug development company focused on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a group of companies with a focus on the developme...

Japanese Cancer Association and Debiopharm Honour Japanese Research

Professors Ichijo and Mano Receive 2008 JCA-Mauvernay Award LAUSANNE, Switzerland, October 29 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, presented Professors Hideno...

Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award

LAUSANNE, Switzerland, October 8 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented Professors Minoru Toyota and Keiichi Nakayama with the 2007 JCA-Mauvernay Award for their outstand...

The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience

LAUSANNE, Switzerland, August 30 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, today presented the 'Debiopharm Life Sciences Award' to Hungarian scientist Dr Zoltan Nusser for his outstan...

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

...tic drug. Under the terms of the agreement, debiopharm and MSM haveformed a partnership to select antibod... completion of the discovery phase, MSM will grant debiopharm a worldwide exclusive licence for the development ...and Asia. MSM will receive milestone payments from debiopharm during the development of the product, as well as ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...2 Monoclonal Antibodies II-52 Vaccines II-52 Radioactive Monoclonal Antibodies II-52 5. Drug Approvals and Clinical Studies II-53 debiopharm Unveils Results of Phase III Study of Trelstar in Prostate Cancer Treatment II-53 Algeta to Start Clinical Study of Alpharadin in HRPC II-53 ...

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

...our drug. Under the terms of the agreement, debiopharm shall pay Moffitt an up-front fee, as well as pred...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group. "Being able to de-activate a key signalling...artment of Drug Discovery at Moffitt. About debiopharm Group ...

Caprion Proteomics Inc. and Applied Bioystems Work Together to Accelerate Protein Biomarker Verification and Validation

...atories, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, ICOS, Bayer-Schering , EMD-Serono, Vertex, debiopharm and Transgene. Caprion also has been awarded two consecutive 5-year US$13 million contracts for Biodefense proteomics research in the area of infectio...

Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions

...europathic pain. Under the terms of the agreement, debiopharm will make an up-front payment to Pharmaleads, as w...therapeutic area of chronic pain management to the debiopharm product portfolio. There is currently an unmet med...d Rolland-Yves Mauvernay, President and Founder of debiopharm Group. "This exclusive licence agreement is...

Covance Purchases Equity Stake in Caprion Proteomics

...atories, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, ICOS, Bayer-Schering , EMD-Serono, Vertex, debiopharm and Transgene. Caprion also has been awarded two major 5-year Biodefense proteomics research contracts in infectious disease with the NIH-NIAID, and w...
Other Tags
(Date:7/26/2014)... 26, 2014 As morcellator lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes that more doctors ... ban uterine morcellation. According to a report from The ... four from California who was diagnosed with a rare ... 10 days after undergoing a laparoscopic hysterectomy where a ...
(Date:7/26/2014)... OH (PRWEB) July 26, 2014 Another DePuy ... DePuy Orthopedics, Inc., has been filed by Wright & Schulte ... filed on behalf of an Erie County, Ohio man ... his left hip and groin since receiving his Pinnacle Hip ... Ohio man will be forced to undergo a complex and ...
(Date:7/26/2014)... According to the "Get Rid Tattoo Naturally" ... comprehensive guide that provides readers with safe and natural ... also teaches them how to fade dark colored tattoos, ... own home for drastic results. , Vkool reveals ... includes step-by-step tutorials and product recommendations for treating different ...
(Date:7/25/2014)... PersonalInjurySolicitorsIreland, a legal claims company ... who have suffered from a variety of injuries, ... new company, and a website, http://www.PersonalInjurySolicitorsIreland.com . ... explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the law firm specialises ... company is always on the client, and everyone ...
(Date:7/25/2014)... July 26, 2014 According to ... Market by Product (vibration monitoring, thermography, ultrasound emission, ... analysis), Component, Application and Geography - Global Forecast ... machine health monitoring market is expected to reach ... to 2020. , Browse 117 market data Tables ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4
(Date:7/25/2014)... an unknown interaction between microorganisms and salt. When ... of salt water and is left to dry, bacteria ... 3D morphologically complex formations, where they hibernate. Afterwards, simply ... was made by chance with a home microscope, but ... journal and may help to find signs of life ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an ... has cut emergency room wait times by an average ... Medical Center, according to a recent study published in ... are using the suite to access data from incoming ... "Using Geneva,s technology platform we have been ...
(Date:7/24/2014)... that characterize sustainable university and college programs designed ... teachers. Specifically, one or more faculty members who ... with institutional motivation and commitment can ensure that ... Math (STEM) teacher shortages are especially acute in ... institutions seeking to increase the number of STEM ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Creating sustainable STEM teacher preparation programs 2
Other Contents